Smart Immune to present details of the phase I/II studies of new T-cell therapy SMART101 at the European Hematology Association (EHA)
May 11, 2023
Smart Immune is a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T-cell therapy platform to fully and rapidly re-arm the immune system, enabling next generation allogeneic T-cell therapies for all.
Through its patented ex vivo lymphoid technology, Smart Immune has developed a T-cell progenitor-based cell therapy platform, called the ProTcell platform. It has been designed to enable rapid and full re-arming of the immune system, so patients can fight life-threatening disorders like cancers and infections.